Verovaccines concludes international pharma cooperation agreement
3 December 2019 Verovaccines enters into first collaboration with a Japanese pharmaceutical company to jointly develop a veterinary vaccine The goal is to develop and commercialize novel, cost-effective vaccines with high safety and efficacy for animal health The company was financed for the seed phase by High-Tech Gruenderfonds, Business Angels and the founders as well […]
Film about the Verovaccines funding project
1 June 2019 https://verovaccines.com/wp-content/uploads/2022/09/VEROVACCiNES_-Virenschutz-durch-Milchhefe.mp4 This documentation (audio in German) by the German GO-Bio funding program (https://go-bio.de/en) gives a short introduction to yeast-based vaccines for animal health. GO-Bio is a life sciences-oriented funding initiative of the Federal Ministry of Education and Research of Germany.
Moving to a new facility
17 July 2018 VEROVACCiNES GmbH recently moved to a new facility on the Technology Center/Weinberg Campus in Halle (Saale), Germany. The 400 square meter facility provides state of the art laboratories for molecularbiology applications (biochemistry, microbial fermentation, recombinant technology and tissue culture). The labs provide significantly more space for the company. This will allow further […]
3.1 million euro public funding granted to VEROVACCiNES GmbH for animal vaccine development.
17 April 2018 VEROVACCiNES GmbH has been awarded 3.1 million euro research funding from the highly competitive funding program GO-Bio (German Federal Ministry of Education and Research) for a 3 year period. „This support will take the development of our yeast-based vaccines a significant step forward. We expect to fully validate our novel technology to […]
VEROVACCiNES GmbH founded in Halle (Saale), Germany.
17 July 2017 VEROVACCiNES GmbH is a successful spin-off from the Martin Luther University Halle-Wittenberg, Germany. The co-founders Dr. Hanjo Hennemann and Prof. Dr. Sven-Erik Behrens entered the management of the company as managing directors. “We are very pleased to get the company started. After achieving a positive votum for our funding application in the […]
Fourth vaccine program (bovine viral diarrhea) validated in initial proof of concept study
14 April 2017 VEROVACCiNES successfully completed trials in its bovine viral diarrhea (BVD) program. “This proof of concept study indicates efficacy of our vaccine candidate in the target animal, though the obtained data require statistical coverage”, Prof. Sven-Erik Behrens said. After having achieved full protection with proprietary subunit marker vaccines in its infectious bursitis-, influenza- […]
VEROVACCiNES selected as Emerging Company at ANIMAL HEALTH INVESTMENT Europe, London UK conference 2017.
22 February 2017 The selection committee of the conference ANIMAL HEALTH INVESTMENT Europe, London UK, selected the startup project VEROVACCiNES as one of 12 presenting emerging companies. VEROVACCiNES is the only “yet to be founded” participant.This conference is dedicated to showcasing to investors the most innovative emerging animal health companies covering the companion, aquaculture and […]